scispace - formally typeset
S

Stuart M. Greenstein

Researcher at Albert Einstein College of Medicine

Publications -  85
Citations -  1987

Stuart M. Greenstein is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 24, co-authored 85 publications receiving 1820 citations. Previous affiliations of Stuart M. Greenstein include University of Pennsylvania & Montefiore Medical Center.

Papers
More filters
Journal ArticleDOI

Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate

TL;DR: Pamidronate treatment was associated with development of adynamic bone histology and whether an improved BMD with adynamicBone histology is useful in maintaining long-term bone health in renal transplant recipients requires further study.
Journal ArticleDOI

Compliance and noncompliance in patients with a functioning renal transplant: A multicenter study

TL;DR: Results of this large, multicenter survey designed to identify variables that affect the likelihood of compliance with immunosuppressive medication regimens and distinguish among noncompliant patients can be used by clinicians to identify patients likely to becomeNoncompliant, by researchers to develop randomized, prospective clinical trials of interventions designed to increase compliance, and by educators to tailor patient education programs.
Journal ArticleDOI

COVID-19 infection in kidney transplant recipients at the epicenter of pandemics.

TL;DR: In multivariable analysis, older age, receipt of deceased-donor transplantation, lack of influenza vaccination in the previous year and higher serum interleukine-6 levels were associated with mortality.
Journal ArticleDOI

Percutaneous transluminal angioplasty. The procedure of choice in the hypertensive renal allograft recipient with renal artery stenosis.

TL;DR: Compared with operation, PTA is a safer and more effective procedure for the initial treatment of RTAS and in patients with functioning kidneys at a mean follow-up period of 30 months.
Journal ArticleDOI

Postrenal Transplant Compliance From the Perspective of African-Americans, Hispanic-Americans, and Anglo-Americans

TL;DR: Findings revealed that 96 (18%) of the transplant recipients had been noncompliant with immunosuppressive medications, including African-American patients, which challenge conventional thinking.